Medical company Summit Medical Group said on Monday that the Department of Ear Nose & Throat/Allergy conducted a clinical trial that led the US Food & Drug Administration (FDA) to approve the nasal spay XHANCE (fluticasone proprionate) for the treatment of nasal polyps in patients 18 years of age or older.
The XHANCE clinical trial is reportedly part of the company's larger initiative to advance medicine.
Currently, the company is involved in 31 active clinical trials, which are critical to the development of new therapies, including finding innovative treatments for cancer, rheumatoid arthritis, type 2 diabetes as well as allergies.
In the US, about 10 million people suffer from the benign growths that block the nasal passages and cause congestion, pain and pressure, sinus infections and difficulty breathing.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886